|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
EPOR Antibody Datasheet
|Order or Inquire for EPOR Antibody product||Quality antibodies||Antibody production services|
|Detection limit is 8 ng/lane in WB|
|Detection limit is 0.078 ng/well in ELISA|
EPOR Antibody Product Information
Recombinant Human EPOR protein (Catalog#10707-H08H)
|Antibody Type :||Mouse Monoclonal Antibody ( Mouse mAb Service Platform )|
Clone ID :
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS with 5% trehalose|
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human EPOR (rh EPOR; Catalog#10707-H08H; NP_000112.1; Met 1-Pro 250). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
EPOR Antibody Usage Guide
No cross-reactivity in ELISA with
Mouse EPORHuman cell lysate (293 cell line)
|Western blot :||This antibody can be used at 1-2 μg/mL with the appropriate secondary reagents to detect Human EPOR in WB. Using a DAB detection system, the detection limit for Human EPOR is approximately 8 ng/lane under non-reducing conditions and reducing conditions.|
|Direct ELISA :||This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human EPOR. The detection limit for Human EPOR is approximately 0.078 ng/well.|
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
EPOR Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|EPOR||Human||EPOR/Fc protein, Recombinant||10707-H02H|
|EPOR||Human||EPOR protein, Recombinant||10707-H08H|
|EPOR||Mouse||EPOR/Fc protein, Recombinant||50031-M03H|
|EPOR||Mouse||EPOR protein, Recombinant||50031-M08H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human EPOR||WB, ELISA||EPOR Antibody||10707-MM01|
|Human EPOR||WB, ELISA||EPOR Antibody||10707-RP01|
|Human EPOR||WB, ELISA||EPOR Antibody (Antigen Affinity Purified)||10707-RP02|
|Human EPOR||WB, ELISA||EPOR Antibody||10707-R004|
|Human EPOR||WB, ELISA||EPOR Antibody||10707-R010|
EPOR Antibody Background
Erythropoietin (EPO) is the major glycoprotein hormone regulator of mammalian erythropoiesis, and is produced by kidney and liver in an oxygen-dependent manner. The biological effects of EPO are mediated by the specific erythropoietin receptor (EPOR) on bone marrow erythroblasts, which transmits signals important for both proliferation and differentiation along the erythroid lineage. EPOR is a type 1 single-transmembrane cytokine receptor, and belongs to the homodimerizing subclass which functions as ligand-induced or ligand-stabilized homodimers. Mouse EPOR contains a tryptophan-serine-X-tryptophan-serine (WSXWS) motif and 1 copy of a cytoplasmic immunoreceptor tyrosine-based inhibitor motif (ITIM) motif, and shares approximately 80% amino acid sequence identity with the human EPOR. Mouse EPOR is expressed in relatively mature erythroid progenitor cells and in EPO-responsive erythroleukemia cells. EPO binding to EPOR triggers auto- or trans-phosphorylation of a protein-tyrosine kinase JAK2 bound to the receptor cytosolic (CT) domain, and subsequently JAK2 activates a variety of intracellular signal substrates including Ras/MAPK, phosphatidylinositol 3-kinase and STAT transcription factors. The stimulated EPOR appears to function in erythroid cell survival through preventing the PCD, and is also suggested to play a neuroprotective role for its expression in mammalian brains.
- Jones, S.S. et al., 1990, Blood. 76: 31-35.
- Liboi, E. et al., 1993, Proc. Natl. Acad. Sci. USA. 23: 11351-11355.
- Yoshimura, A. and Arai, K. 1996, Oncologist. 1: 337-339.
- Kawakami, M. et al., 2001, J. Biol. Chem. 276: 39469-39475.
- Wojchowski, D.M. et al., 1999, Exp. Cell. Res. 253: 143-156.
- Witthuhn, B.A. et al., 1993, Cell. 74: 227-236.
EPOR related areas, pathways, and other information